These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 30396964)

  • 21. hMLH1 and hMSH2 expression in human hepatocellular carcinoma.
    Wang L; Bani-Hani A; Montoya DP; Roche PC; Thibodeau SN; Burgart LJ; Roberts LR
    Int J Oncol; 2001 Sep; 19(3):567-70. PubMed ID: 11494037
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer.
    Hurwitz HI; Fehrenbacher L; Hainsworth JD; Heim W; Berlin J; Holmgren E; Hambleton J; Novotny WF; Kabbinavar F
    J Clin Oncol; 2005 May; 23(15):3502-8. PubMed ID: 15908660
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mismatch repair protein expression is an independent prognostic factor in sporadic colorectal cancer.
    Ohrling K; Edler D; Hallström M; Ragnhammar P
    Acta Oncol; 2010 Aug; 49(6):797-804. PubMed ID: 20307245
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunohistochemistry detects mismatch repair gene defects in colorectal cancer.
    Hameed F; Goldberg PA; Hall P; Algar U; van Wijk R; Ramesar R
    Colorectal Dis; 2006 Jun; 8(5):411-7. PubMed ID: 16684085
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial.
    Goldberg RM; Sargent DJ; Morton RF; Fuchs CS; Ramanathan RK; Williamson SK; Findlay BP; Pitot HC; Alberts S
    J Clin Oncol; 2006 Jul; 24(21):3347-53. PubMed ID: 16849748
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multicentre phase II study using increasing doses of irinotecan combined with a simplified LV5FU2 regimen in metastatic colorectal cancer.
    Duffour J; Gourgou S; Desseigne F; Debrigode C; Mineur L; Pinguet F; Poujol S; Chalbos P; Bressole F; Ychou M
    Cancer Chemother Pharmacol; 2007 Aug; 60(3):383-9. PubMed ID: 17124595
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
    Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H
    Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy.
    Samimi G; Fink D; Varki NM; Husain A; Hoskins WJ; Alberts DS; Howell SB
    Clin Cancer Res; 2000 Apr; 6(4):1415-21. PubMed ID: 10778972
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized phase II trial of TEGAFIRI (tegafur/uracil, oral leucovorin, irinotecan) compared with FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) in patients with unresectable/recurrent colorectal cancer.
    Shigeta K; Hasegawa H; Okabayashi K; Tsuruta M; Ishii Y; Endo T; Ochiai H; Kondo T; Kitagawa Y
    Int J Cancer; 2016 Aug; 139(4):946-54. PubMed ID: 27061810
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association between family history and mismatch repair in colorectal cancer.
    Coggins RP; Cawkwell L; Bell SM; Crockford GP; Quirke P; Finan PJ; Bishop DT
    Gut; 2005 May; 54(5):636-42. PubMed ID: 15831908
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinoma.
    Geisler JP; Goodheart MJ; Sood AK; Holmes RJ; Hatterman-Zogg MA; Buller RE
    Cancer; 2003 Nov; 98(10):2199-206. PubMed ID: 14601090
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [KRAS mutation does not influence oxaliplatin or irinotecan efficacy, in association with bevacizumab, in first line treatment of metastatic colorectal cancer].
    Cabart M; Frénel JS; Campion L; Ramée JF; Dupuis O; Senellart H; Hiret S; Douillard JY; Bennouna J
    Bull Cancer; 2016 Jun; 103(6):541-51. PubMed ID: 27155924
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
    Peeters M; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; Tzekova V; Collins S; Oliner KS; Rong A; Gansert J
    J Clin Oncol; 2010 Nov; 28(31):4706-13. PubMed ID: 20921462
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized phase II trial of pemetrexed plus irinotecan (ALIRI) versus leucovorin-modulated 5-FU plus irinotecan (FOLFIRI) in first-line treatment of locally advanced or metastatic colorectal cancer.
    Underhill C; Goldstein D; Gorbounova VA; Biakhov MY; Bazin IS; Granov DA; Hossain AM; Blatter J; Kaiser C; Ma D
    Oncology; 2007; 73(1-2):9-20. PubMed ID: 18334829
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Diagnostic and prognostic values of repair protein hMLH1, hMSH2 and protein CD34 immunoexpression in sporadic colorectal cancer].
    Słomka M; Stasikowska O; Wagrowska-Danilewicz M; Danilewicz M; Małecka-Panas E
    Pol Merkur Lekarski; 2010 Dec; 29(174):351-6. PubMed ID: 21298983
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Microsatellite instability and hMLH1 and hMSH2 expression analysis in soft tissue sarcomas.
    Kawaguchi K; Oda Y; Takahira T; Saito T; Yamamoto H; Kobayashi C; Tamiya S; Oda S; Iwamoto Y; Tsuneyoshi M
    Oncol Rep; 2005 Feb; 13(2):241-6. PubMed ID: 15643505
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunohistochemical analysis of expression and allelotype of mismatch repair genes (hMLH1 and hMSH2) in bladder cancer.
    Kassem HS; Varley JM; Hamam SM; Margison GP
    Br J Cancer; 2001 Feb; 84(3):321-8. PubMed ID: 11161395
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of hMLH1 methylation, mismatch repair deficiency and microsatellite instability on chemoresistance of testicular germ-cell tumors.
    Olasz J; Mándoky L; Géczi L; Bodrogi I; Csuka O; Bak M
    Anticancer Res; 2005; 25(6B):4319-24. PubMed ID: 16309235
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined treatment with bevacizumab and standard chemotherapy restores abnormal immune parameters in advanced colorectal cancer patients.
    Tsavaris N; Voutsas IF; Kosmas C; Gritzapis AD; Baxevanis CN
    Invest New Drugs; 2012 Feb; 30(1):395-402. PubMed ID: 20820907
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BAT-26 microsatellite instability does not correlate with the loss of hMLH1 and hMSH2 protein expression in sporadic endometrial cancers.
    Miturski R; Bogusiewicz M; Tarkowski R; Ciotta C; Bignami M; Burnouf D; Jakowicki JA
    Oncol Rep; 2003; 10(4):1039-43. PubMed ID: 12792767
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.